FDA Increases Antiangiogenic Treatment Options for Kidney Cancer
Late last week, the U.S. Food and Drug Administration (FDA) added another antiangiogenic therapeutic to the armamentarium for oncologists...
Author:
Karen Honey, PhD
Late last week, the U.S. Food and Drug Administration (FDA) added another antiangiogenic therapeutic to the armamentarium for oncologists...
The U.S. Food and Drug Administration (FDA) recently approved the use of molecularly targeted therapeutic afatinib (Gilotrif) for treating...
Last week, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of the antiangiogenic...
Earlier this month, the U.S. Food and Drug Administration (FDA) approved a new colorectal cancer screening test, the ‘System,...
Last week, the U.S. Food and Drug Administration (FDA) added another therapeutic to the armamentarium for hematologist-oncologists when it...
Last week, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of crizotinib (Xalkori)...
At the end of last week, the U.S. Food and Drug Administration (FDA) approved the immunotherapeutic obinutuzumab (Gazyva) for...
Late last week, the U.S. Food and Drug Administration (FDA) approved a new treatment for one of the most...
The dawning of the new year marked the 75th anniversary of the publication of the first issue of Cancer...
Cancer awareness months provide an opportunity to increase public knowledge of all aspects of a particular cancer, from prevention,...